Search

Your search keyword '"Pistelli, M"' showing total 201 results
Start Over Author "Pistelli, M"
201 results on '"Pistelli, M"'

1. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Alù, M., Ancona, C., Andreis, D., Bajardi, E., Benedetto, C., Berardi, R., Bordin, E., Butti, C., Capri, G., Cicchiello, F., Cocciolone, V., Dester, M., D'Onofrio, L., Febbraro, A., Ferrarini, I., Fotia, V., Gervasi, E., Guaitoli, G., Licata, L., Liscia, N., Mentuccia, L., Miraglio, E., Nicolini, M., Paternò, E., Pedani, F., Pellegrini, D., Petrucelli, L., De Laurentiis, M., Pizzuti, L., Pogliani, C., Riva, F., Cazzaniga, M.E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G.V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M.C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M.R., Vici, P., Zambelli, A., Clivio, L., and Torri, V.

Published
2017
Full Text
View/download PDF

2. 225P Platinum-based chemotherapy and PARP Inhibitors for BRCA mutated metastatic breast cancer (LATER-BC): Retrospective multicentre analysis of post-progression treatments

Author

Valenza, C., primary, Trapani, D., additional, Sposetti, C., additional, Bielo, L. Boscolo, additional, Marra, A., additional, Giarratano, T., additional, Cortesi, L., additional, Moscetti, L., additional, Pistelli, M., additional, Berardi, R., additional, Zambelli, A., additional, Guarneri, V., additional, Vernieri, C., additional, and Curigliano, G., additional

Published
2023
Full Text
View/download PDF

3. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer

Author

Viansone, A., primary, Pellegrino, B., additional, Omarini, C., additional, Pistelli, M., additional, Boggiani, D., additional, Sikokis, A., additional, Uliana, V., additional, Zanoni, D., additional, Tommasi, C., additional, Bortesi, B., additional, Bonatti, F., additional, Piacentini, F., additional, Cortesi, L., additional, Camisa, R., additional, Sgargi, P., additional, Michiara, M., additional, and Musolino, A., additional

Published
2022
Full Text
View/download PDF

4. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Author

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, and Cascinu S

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Rossana Berardi, Matteo Santoni, Francesca Morgese, Zelmira Ballatore, Agnese Savini, Azzurra Onofri, Paola Mazzanti, Mirco Pistelli, Chiara Pierantoni, Mariagrazia De Lisa, Miriam Caramanti, Silvia Pagliaretta, Chiara Pellei, Stefano CascinuMedical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM Lancisi – G Salesi, Ancona, ItalyAbstract: In the last decade, better understanding of the role of epidermal growth factor receptor in the pathogenesis and progression of non-small cell lung cancer has led to a revolution in the work-up of these neoplasms. Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for the treatment of non-small cell lung cancer, demonstrating an improvement in progression-free and overall survival, particularly in patients harboring activating EGFR mutations. Nevertheless, despite initial responses and long-lasting remissions, resistance to tyrosine kinase inhibitors invariably develops, most commonly due to the emergence of secondary T790M mutations or to the amplification of mesenchymal–epithelial transition factor (c-Met), which inevitably leads to treatment failure. Several clinical studies are ongoing (http://www.clinicaltrials.gov/), aimed to evaluate the efficacy and toxicity of combined approaches and to develop novel irreversible or multitargeted tyrosine kinase inhibitors and mutant-selective inhibitors to overcome such resistance. This review is an overview of ongoing Phase I, II, and III trials of novel small molecule epidermal growth factor receptor inhibitors and combinations in non-small cell lung cancer patients.Keywords: clinical trials, combined targeted therapy, epidermal growth factor receptor, non-small cell lung cancer, novel targeted agents, tyrosine kinase inhibitors

Published
2013

5. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, Matteo, Butti, C., Liscia, N., Pogliani, C., Capri, Giorgia, Alu', Matteo, Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, Enrico, Guaitoli, G., Ferrarini, I., Gervasi, Elisea, Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, Anna, Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, Ruggero Astolfo, Clivio, L., Torri, V., Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cazzaniga, M. E, Bianchi, G. V, Cursano, M. C, Valerio, M. R, Torri, V., De Laurentiis, Michelino, Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, E., Guaitoli, G., Ferrarini, I., Gervasi, E., Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Cazzaniga, M., Ala, M., ARRIVAS BAJARDI, E., Paternã², E., Bianchi, G., Cursano, M., and Valerio, M.

Subjects
0301 basic medicine, Oncology, Receptor, ErbB-2, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Dose-intensity, Exemestane, 80 and over, Neoplasm Metastasis, Fulvestrant, Aged, 80 and over, education.field_of_study, Advanced breast cancer, Dose-intensity, Everolimus, Fulvestrant, Hormone-receptor positive, Advanced breast cancer, Everolimus, Hormone-receptor positive, Adult, Aged, Androstadienes, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Surgery, General Medicine, Everolimu, 030220 oncology & carcinogenesis, Receptor, medicine.drug, medicine.medical_specialty, Population, Socio-culturale, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Adverse effect, education, Gynecology, business.industry, fungi, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, business
Abstract

Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33–83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1–7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4–58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). Conclusions The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.

Published
2017

6. C65 - Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes

Author

Bertolini, I., Diodati, L., Fontana, A., De Angelis, C., Cantini, L., Cecconi, S., Montagnani, I., Salvadori, B., Ferrarini, I., Ferrari, P., Michelotti, A., Landucci, E., Fanelli, G., Scatena, C., Naccarato, A.G., Berardi, R., Pistelli, M., and Falcone, A.

Published
2017
Full Text
View/download PDF

15. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

Author

Cazzaniga M. E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M. R., Zustovich F., Cazzaniga M.E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M.R., Zustovich F., Cazzaniga, M, Danesi, R, Girmenia, C, Invernizzi, P, Elvevi, A, Uguccioni, M, Amaducci, L, Atzori, F, Blasi, L, Butti, C, Collova, E, De Conciliis, E, Fabi, A, Febbraro, A, Garrone, O, Gianni, L, Giotta, F, La Verde, N, Michelotti, A, Palumbo, R, Paris, I, Pistelli, M, Pizzuti, L, Rubino, D, Valerio, M, and Zustovich, F

Subjects
0301 basic medicine, Cancer Research, Review, Disease, chemistry.chemical_compound, 0302 clinical medicine, Ribociclib, Molecular Targeted Therapy, Abemaciclib, Clinical Trials as Topic, Disease Management, Metastatic breast cancer, Everolimu, Oncology, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Advanced breast cancer, Receptors, Progesterone, Breast Neoplasm, medicine.drug, Human, medicine.medical_specialty, Neutropenia, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Hormonal, Protein Kinase Inhibitor, Breast Neoplasms, Palbociclib, 03 medical and health sciences, Breast cancer, medicine, Biomarkers, Tumor, Humans, Everolimus, Intensive care medicine, Adverse effect, Protein Kinase Inhibitors, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, MED/06 - ONCOLOGIA MEDICA, business, Drug-Related Side Effects and Adverse Reaction
Abstract

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods: We reviewed the current evidence on the drug safety of targeted agents for metastatic breast cancer currently used in clinical practice in Italy, supported by the clinical experience of Italian oncologists with expertise in the field. Results: All oncologists had used CDK4/6 inhibitors in clinical practice and/or within a clinical trial. The clinical management of toxicities, including dose adjustments, treatment interruptions, and concerns regarding special populations is discussed, and the management of relevant adverse events, related to individual agents and class-specific, toxicities is reviewed. Hematologic toxicities have the greatest impact on clinical management of the disease and on patients. Although toxicities associated with the new treatments result in more visits to the physician and more time and attention with patients, they are manageable, with no need for the oncologist to consult with specialist physicians. Conclusions: Based on the available evidence and current guidelines, we propose a series of practical recommendations for multidisciplinary clinical management of the various toxicities associated with the addition of targeted agents to endocrine therapy.

Published
2019

16. 1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study

Author

Berardi, R., primary, Mentrasti, G., additional, Crocetti, S., additional, La Verde, N., additional, Chiari, R., additional, Cona, M.S., additional, Nicolardi, L., additional, De Filippis, C., additional, Oldani, S., additional, Pecci, F., additional, Venanzi, F., additional, Rocchi, M.B.L., additional, Savini, A., additional, Cantini, L., additional, and Pistelli, M., additional

Published
2021
Full Text
View/download PDF

17. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Author

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L., La Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Torri, V., On behalf of The EVA Study Group, Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, D'Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter, Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, On behalf of The EVA Study, G, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio MR., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M.C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., and On behalf of The EVA Study Group

Subjects
medicine.medical_specialty, Socio-culturale, Hormone-receptor positive, Exemestane, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Elderly, Weight loss, Internal medicine, Advanced breast cancer, Everolimus, Oncology, medicine, 030212 general & internal medicine, Stomatitis, Pneumonitis, business.industry, Cancer, medicine.disease, Rash, Everolimu, chemistry, 030220 oncology & carcinogenesis, MED/06 - ONCOLOGIA MEDICA, medicine.symptom, business, Research Paper, medicine.drug
Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018

20. Abstract P6-14-01: The effect trial: A randomized phase II trial evaluating two different doses of weekly (W) NAB-paclitaxel (NP) as first-line chemotherapy in older breast cancer (BC) patients (pts)

Author

Biganzoli, L, primary, Berardi, R, additional, Pedersini, R, additional, Minisini, AM, additional, Caremoli, ER, additional, Spazzapan, S, additional, Lima, JS, additional, Baldari, D, additional, Orlando, L, additional, Magnolfi, E, additional, Pistelli, M, additional, Brunello, A, additional, Zafarana, E, additional, Bernardo, A, additional, Leo, S, additional, Colleoni, M, additional, Donati, S, additional, De Placido, S, additional, Parolin, V, additional, Vitale, S, additional, Di Leo, A, additional, Puglisi, F, additional, Boni, L, additional, and Cinieri, S, additional

Published
2018
Full Text
View/download PDF

21. Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes

Author

Bertolini, I., primary, Diodati, L., additional, Fontana, A., additional, De Angelis, C., additional, Cantini, L., additional, Cecconi, S., additional, Montagnani, I., additional, Salvadori, B., additional, Ferrarini, I., additional, Ferrari, P., additional, Michelotti, A., additional, Landucci, E., additional, Fanelli, G., additional, Scatena, C., additional, Naccarato, A.G., additional, Berardi, R., additional, Pistelli, M., additional, and Falcone, A., additional

Published
2017
Full Text
View/download PDF

22. Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): old drugs, new results. The multicenter VICTOR-6 study

Author

Cazzaniga, M., primary, Orlando, L., additional, Melegari, E., additional, Arcangeli, V., additional, Butera, A., additional, Pinotti, G., additional, Vallini, I., additional, Mocerino, C., additional, Giovanardi, F., additional, Cretella, E., additional, Gambaro, A., additional, Pistelli, M., additional, Donati, S., additional, Pizzuti, L., additional, Spagnuolo, A., additional, Putzu, C., additional, Leonardi, V., additional, De Angelis, C., additional, Pedroli, S., additional, and Torri, V., additional

Published
2017
Full Text
View/download PDF

23. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cazzaniga, M.E., primary, Airoldi, M., additional, Arcangeli, V., additional, Artale, S., additional, Atzori, F., additional, Ballerio, A., additional, Bianchi, G.V., additional, Blasi, L., additional, Campidoglio, S., additional, Ciccarese, M., additional, Cursano, M.C., additional, Piezzo, M., additional, Fabi, A., additional, Ferrari, L., additional, Ferzi, A., additional, Ficorella, C., additional, Frassoldati, A., additional, Fumagalli, A., additional, Garrone, O., additional, Gebbia, V., additional, Generali, D., additional, La Verde, N., additional, Maur, M., additional, Michelotti, A., additional, Moretti, G., additional, Musolino, A., additional, Palumbo, R., additional, Pistelli, M., additional, Porpiglia, M., additional, Sartori, D., additional, Scavelli, C., additional, Schirone, A., additional, Turletti, A., additional, Valerio, M.R., additional, Vici, P., additional, Zambelli, A., additional, Clivio, L., additional, Torri, V., additional, Alù, M., additional, Ancona, C., additional, Andreis, D., additional, Bajardi, E., additional, Benedetto, C., additional, Berardi, R., additional, Bordin, E., additional, Butti, C., additional, Capri, G., additional, Cicchiello, F., additional, Cocciolone, V., additional, Dester, M., additional, D'Onofrio, L., additional, Febbraro, A., additional, Ferrarini, I., additional, Fotia, V., additional, Gervasi, E., additional, Guaitoli, G., additional, Licata, L., additional, Liscia, N., additional, Mentuccia, L., additional, Miraglio, E., additional, Nicolini, M., additional, Paternò, E., additional, Pedani, F., additional, Pellegrini, D., additional, Petrucelli, L., additional, De Laurentiis, M., additional, Pizzuti, L., additional, Pogliani, C., additional, and Riva, F., additional

Published
2017
Full Text
View/download PDF

24. Breast cancer secondary prevention: get fit to feel healthy

Author

Pistelli, M., primary, Bastianelli, L., additional, Della Mora, A., additional, Romeo, M., additional, Ballatore, Z., additional, Natalucci, V., additional, Capecci, M., additional, Ceravolo, M.G., additional, Serrani, R., additional, Ricci, M., additional, Fumelli, D., additional, Taus, M., additional, Nicolai, A., additional, and Berardi, R., additional

Published
2017
Full Text
View/download PDF

25. Stromal peritumoral and intratumoral infiltrating lymphocytes: how immunity influences prognosis in triple negative breast cancer

Author

Della Mora, A., primary, Bastianelli, L., additional, Pistelli, M., additional, Santinelli, A., additional, Cantini, L., additional, Doria, A., additional, Merloni, F., additional, Lucarelli, A., additional, Savini, A., additional, Maccaroni, E., additional, Ballatore, Z., additional, Pagliacci, A., additional, and Berardi, R., additional

Published
2017
Full Text
View/download PDF

27. “Feel beautiful to feel alive”

Author

Tonnini, C., primary, De Papa, A., additional, Loiacono, F., additional, Ricci, G., additional, Romeo, M., additional, Giampieri, R., additional, Pistelli, M., additional, Savini, A., additional, Francoletti, M., additional, and Berardi, R., additional

Published
2017
Full Text
View/download PDF

29. Pathogenetic mutations in BRCA related triple negative breast cancer

Author

Bini, F., primary, Ballatore, Z., additional, Bianchi, F., additional, Maccaroni, E., additional, Belvederesi, L., additional, Brugiati, C., additional, Pagliaretta, S., additional, Murrone, A., additional, Savini, A., additional, Pistelli, M., additional, Bracci, R., additional, and Berardi, R., additional

Published
2017
Full Text
View/download PDF

30. Prognostic impact of CA15-3 pre-treatment levels in ovarian cancer patients

Author

Maccaroni, E., primary, Giampieri, R., additional, Del Prete, M., additional, Principi, G., additional, Bracci, R., additional, Calcinari, A., additional, Della Mora, A., additional, Bianchi, F., additional, Belvederesi, L., additional, Brugiati, C., additional, Pagliaretta, S., additional, Pistelli, M., additional, Savini, A., additional, Pagliacci, A., additional, Ballatore, Z., additional, Bini, F., additional, Baleani, M.G., additional, Cantini, L., additional, Murrone, A., additional, and Berardi, R., additional

Published
2017
Full Text
View/download PDF

42. BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer

Author

Pistelli, M., primary, Santinelli, A., additional, Santoni, M., additional, Piva, F., additional, Bianchi, F., additional, Belvederesi, L., additional, Biscotti, T., additional, De Lisa, M., additional, Ballatore, Z., additional, Occhipinti, G., additional, Pagliacci, A., additional, Maccaroni, E., additional, Bracci, R., additional, Battelli, N., additional, Cantini, L., additional, Bastianelli, L., additional, Berardi, R., additional, and Cascinu, S., additional

Published
2016
Full Text
View/download PDF

43. Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer (OC) patients: a single centre experience

Author

Maccaroni, E., primary, Bracci, R., additional, Giampieri, R., additional, Bianchi, F., additional, Belvederesi, L., additional, Brugiati, C., additional, Pagliaretta, S., additional, De Mora, Alla, additional, Tronconi, F., additional, Pistelli, M., additional, Pagliacci, A., additional, Battelli, N., additional, Ballatore, Z., additional, De Lisa, M., additional, and Berardi, R., additional

Published
2016
Full Text
View/download PDF

44. Triple-negative breast cancer and BRCA mutation: looking at the future

Author

Ballatore, Z., primary, Pistelli, M., additional, Bracci, R., additional, Bianchi, F., additional, Maccaroni, E., additional, Belvederesi, L., additional, Brugiati, C., additional, Pagliaretta, S., additional, De Lisa, M., additional, Della Mora, A., additional, Cantini, L., additional, Bastianelli, L., additional, Pagliacci, A., additional, Battelli, N., additional, and Berardi, R., additional

Published
2016
Full Text
View/download PDF

49. Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients: a single Centre experience

Author

Maccaroni, E., primary, Bracci, R., additional, Giampieri, R., additional, Bianchi, F., additional, Belvederesi, L., additional, Brugiati, C., additional, Pagliaretta, S., additional, Della Mora, A., additional, Tronconi, F., additional, Pistelli, M., additional, Pagliacci, A., additional, Battelli, N., additional, Ballatore, Z., additional, De Lisa, M., additional, and Berardi, R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results